CAMBRIDGE, Mass., Feb. 22 /PRNewswire/ -- Xanthus Life Sciences, Inc., a privately-held oncology drug development company, today announced that it has changed its corporate name to Xanthus Pharmaceuticals, Inc. The name change aligns the Company's corporate name with its strategic focus to build a differentiated specialty pharmaceuticals business.
"The last two years' efforts have focused on the development of the Company's clinical pipeline, which today includes two exciting compounds in clinical development and a third expected to enter the clinic later this year," stated Richard T. Dean, Ph.D., President and CEO of Xanthus. "2006 will be an important building year for the Company as we develop our rapidly evolving pipeline and seek to in-license additional compounds to complement our portfolio. As such, we felt a change in our corporate name to Xanthus Pharmaceuticals, Inc. more appropriately describes our strategic focus."
About Xanthus Pharmaceuticals, Inc.
Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel, clinical-stage, small-molecule oncology candidates through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialization. The Company is applying its expertise both to advance its current pipeline and expand it into indications of unmet medical need beyond oncology.
Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec. More information is available at http://www.xanthus.com.
Contacts:
Kari Watson, MacDougall Biomedical Communications, Inc. -- kwatson@macbiocom.com or (508) 647-0209
John A. McCarthy, Jr., Senior Vice President & CFO, Xanthus Pharmaceuticals, Inc. -- john.mccarthy@xanthus.com or (617) 225-0522 x 125
Xanthus Pharmaceuticals, Inc.CONTACT: Kari Watson, MacDougall Biomedical Communications, Inc.,+1-508-647-0209, kwatson@macbiocom.com; or John A. McCarthy, Jr., SeniorVice President & CFO, of Xanthus Pharmaceuticals, Inc., +1-617-225-0522ext. 125, john.mccarthy@xanthus.com
Web site: http://www.xanthus.com/
